21 April 2020 - This article begins with a short review of the existing taxonomy of managed entry agreements and includes a history of their implementation.
The novelty of the article lies in several highlights, including the introduction of service-based agreements and a proposed structure for their taxonomy, robust literature challenging managed entry agreements’ ability to achieve their goal to address uncertainty, and elaboration on managed entry agreements reintroduced as hidden differential pricing.
In a time when innovative, highly expensive therapies are reaching the market, service-based agreements and establishing the appropriate conditions will be critical to establish sustainable healthcare, rendering this article invaluable for manufacturers seeking faster market access.